Gosset Ownership
Private
Employees
~50
Therapeutic Areas
Stage
Preclinical
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Acelot General Information
Acelot’s lead program ACE-2223 is a first-in-class orally bioavailable small molecule that disrupts misfolded TDP43 and restores its function. Preclinical data show blood-brain barrier permeability and efficacy in reducing pathological TDP43 aggregates as well as improving neuroinflammation and motor function. The company has a robust pipeline of hit-to-lead discovery compounds across multiple indications.
Contact Information
Website
Primary Industry
Biotech
Corporate Office
Santa Barbara, California
United States
United States
Drug Pipeline
ACE-2223
Pre-clinicalKey Partnerships
Acelot Funding
No funding data available
To view Acelot's complete valuation and funding history, request access »